Investigating a new treatment for depression linked to inflammation
Effects of the Next Generation TNF Inhibitor (XPro1595) on Inflammation-related Deficits in Reward Circuitry and Motivation in Depression
This study is looking at how a new treatment might help people with treatment-resistant depression by reducing inflammation in the body, which could improve symptoms like lack of motivation, especially for those who have high levels of inflammation.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Inmune Bio, INC. NIH-funded |
| Lab location | 1 site (Boca Raton, UNITED STATES) |
| Project ID | NIH-10263372 on NIH RePORTER |
What this research studies
This research focuses on treatment-resistant depression (TRD), a severe condition affecting many patients who do not respond to standard antidepressants. The study explores the role of inflammation in TRD, particularly how elevated levels of inflammatory markers like TNF and CRP may hinder treatment effectiveness. By testing a new TNF inhibitor, XPro1595, the research aims to determine if reducing inflammation can alleviate symptoms, especially the lack of motivation often seen in depression. Patients with high inflammation levels may benefit most from this approach.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with treatment-resistant depression who exhibit high levels of inflammation.
Not a fit: Patients who do not have treatment-resistant depression or those without elevated inflammatory markers may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for patients suffering from treatment-resistant depression.
How similar studies have performed: Previous research has shown promise in using anti-inflammatory treatments for depression, suggesting that this approach could be a significant advancement.
Where this research is happening
Boca Raton, UNITED STATES
- Inmune Bio, INC. — Boca Raton, United States (Active)
Researchers
- Principal investigator: Barnum, Christopher J — Inmune Bio, INC.
- Study coordinator: Barnum, Christopher J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.